tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Jason Gerberry, 297 are a BUY (69.07%), 39 are a SELL (9.07%), 94 are a HOLD (21.86%).
Analyst Jason Gerberry, currently employed at BAML, carries an average stock price target met ratio of 58.35% that have a potential upside of 29.19% achieved within 272 days.
Jason Gerberry’s has documented 860 price targets and ratings displayed on 70 stocks. The coverage is on Healthcare, Industrials, Energy sectors.
Most recent stock forecast was given on PCVX, Vaxcyte at 28-Sep-2026.
Analyst best performing recommendations are on LQDA (LIQUIDIA TECHNOLOGIES).
The best stock recommendation documented was for PROK (PROKIDNEY CORP.) at 6/30/2025. The price target of $1 was fulfilled within 8 days with a profit of $0.41 (69.49%) receiving and performance score of 86.86.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 19-Feb-2026
$325
$40.2 (14.12%)
$300
Buy Since 04-Feb-2020
$288
$3.2 (1.12%)
$288
13 days ago
(09-Oct-2026)
45/45 (100%)
$11.53 (4.17%)
407
Hold Since 06-Jan-2026
$275
$-9.8 (-3.44%)
$260
13 days ago
(09-Oct-2026)
5/5 (100%)
$-1.47 (-0.53%)
76
Buy Since 16-Oct-2020
$300
$15.2 (5.34%)
$280
14 days ago
(08-Oct-2026)
20/21 (95.24%)
$27.58 (10.12%)
441
Buy Since 15-Nov-2023
$290
$5.2 (1.83%)
$285
14 days ago
(08-Oct-2026)
31/32 (96.88%)
$17.58 (6.45%)
251
Which stock is Jason Gerberry most bullish on?
Which stock is Jason Gerberry most reserved on?
What Year was the first public recommendation made by Jason Gerberry?
